Eumentis Therapeutics Inc.
生物技术研究
San Diego，CA 531 位关注者
Phase 2 neuroscience biotech focused on schizophrenia
关于我们
EuMentis Therapeutics Inc. is a privately held, clinical stage biotech company focused on the development of novel therapeutics to treat neuropsychiatric conditions with high unmet need. The Company’s lead product, EM-221, is a best-in-class, oral, PDE10A inhibitor designed to modulate the dopamine D2 pathway specifically in the striatum. EuMentis has completed three successful Phase 1 studies and plans to initiate a Phase 2b study of EM-221 for the treatment of schizophrenia in 2H 2025.
- 网站
-
www.eumentistx.com
Eumentis Therapeutics Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- San Diego，CA
- 类型
- 私人持股
- 创立
- 2019
- 领域
- Drug Development、Neuroscience、Autism和Tourette Syndrome
地点
-
主要
获取路线
US，CA，San Diego，92075